MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $44.00 price target on the stock.
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.